Axsome Therapeutics (AXSM) has recorded a 29.06% compound annual growth rate over the past five years, and the article notes that sustaining that pace for nine more years would turn $5,000 into $49,670. The company's growth since 2021 has been driven largely by clinical and regulatory progress, including Auvelity, which treats depression and agitation associated with Alzheimer's disease, an indication the article calls fresh in a large market with few approved options. Axsome may earn approval for AXS-12, a treatment for cataplexy associated with narcolepsy, by May 2027, and it has several Phase 3 programs. With a $7.5 billion market cap, the same growth rate over nine years would imply a $74.5 billion company, which the author says would require near-flawless execution and significant commercial penetration. The author judges this highly unlikely, though considers the company's prospects attractive and says it could again beat the market over the long run.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalsvaluationclinical trials
Open a keyword to see other news on the same topic.
Related news
- Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?
Over the past six months, AXSM returned -7% and NBIX returned 12%, according to the article. Axsome's Q2 2026 revenue rose 46% to $218.4 million, driven largely by AUVELITY sales of $180.3 million, up 51%, and new-to-brand prescriptions for patients aged 65 and older rose 126% in the first eight weeks of the Alzheimer's-related agitation launch. Axsome still reported a $51.3 million net loss in Q2 and a $320 million cash balance. Neurocrine's revenue grew 39% to $959 million, with INGREZZA at $716 million and CRENESSITY at $184 million, and it posted $2.85 in non-GAAP EPS for Q2. At 32.15x forward earnings for Axsome versus 14.12x for Neurocrine, the article says Neurocrine is cheaper, while Axsome must show that its faster growth can turn into sustained profitability.
- ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst Optimism
The modeled fair value for ORIC Pharmaceuticals moved from US$20.67 to US$21.93, a small change tied to analyst views on enozertinib and rinzimetostat. Several firms, including Stifel, JPMorgan and H.C. Wainwright, raised price targets into a US$18 to US$27 range, with JPMorgan describing enozertinib as an underappreciated driver. BTIG and Leerink initiated coverage with US$26 targets, while one analyst noted the stock was down 5% at US$12.89 in morning trading on the day of the lung cancer data update. The fair value model also changed the net profit margin assumption from 17.25% to 15.91% and the future P/E from 753.08x to 971.94x.
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx reported third-quarter 2026 global product net sales of VYVGART of $1.7 billion, up 54% year over year and 13% quarter over quarter. Positive Phase 3 ALKIVIA results showed consistent treatment effects in IMNM and dermatomyositis, with an sBLA for IMNM on track for submission by year-end 2026. The company submitted an sBLA for ocular myasthenia gravis to the FDA, and a pediatric gMG sBLA was accepted for priority review with a PDUFA target date in February 2027. Phase 3 EMPASSION topline results for empasiprubart in MMN are expected in December 2026, while FB102 is advancing to Phase 3 in celiac disease. argenx continues to target treating 50,000 patients, securing 10 labeled indications and advancing five candidates into registrational development by 2030.
- Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Viking Therapeutics has started two phase 3 trials, SUNRISE-1 and SUNRISE-2, for the oral form of its weight loss drug VK2735, alongside its ongoing injectable phase 3 trials. Investors had been shaken by the phase 2 oral trial (VENTURE-Oral), where 20% of treated participants discontinued due to adverse events and the stock fell sharply, although efficacy over 13 weeks was good. The author argues the phase 3 design is different: 13% of the phase 2 placebo group also stopped due to adverse events, phase 2 used a more aggressive titration, and phase 3 runs 68 weeks. CEO Brian Lian said that in phase 2 patients took 4 tablets that were fairly large, and phase 3 aims for smaller tablets and fewer of them. Phase 3 doses are also lower, at 27.5 mg, 35 mg and 55 mg, compared with 15 mg to 120 mg in phase 2.
- Where Will CRISPR Therapeutics Stock Be in 2030?
Shares of CRISPR Therapeutics have fallen about 47% since mid-October 2021, while the S&P 500 has gained almost 73% as of writing, despite clinical and regulatory progress over the past five years. Casgevy, developed with Vertex Pharmaceuticals, was approved in 2023 and early 2024 for transfusion-dependent beta-thalassemia and sickle cell disease, making it the company's first commercial product and the first approved CRISPR-based gene-editing therapy. Other candidates include CTX310, aimed at lowering LDL cholesterol and triglycerides, where Phase 1 data showed significant decreases in both; zugo-cel for autoimmune diseases and blood cancers; and CTX611, an anticoagulant that could be given twice a year. Casgevy's label now covers patients as young as two, adding about 5,500 U.S. patients at $2.2 million per treatment course. The article warns of possible clinical failures and the costly, one-time nature of many gene-editing therapies, which makes profitability uncertain.
- Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed?
Syndax said its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint of slowing lung function decline, so it will halt further IPF development for the drug while other trials continue. Safety in IPF was comparable to placebo, and ongoing studies and the approved chronic GVHD use of Niktimvo are unaffected. The article views the setback as a narrowing of axatilimab's opportunity rather than a franchise-level issue, with Revuforj and Niktimvo still the core commercial pillars. However, Syndax remains loss-making and spends roughly US$400 million a year on R&D and SG&A, so revenue growth is the key factor to watch.
Related markets
Latest news
- Why Big Tech stocks should be priced more like utility companies
The discussion argues that AI has pushed Big Tech toward a business model closer to utilities, so investors may price the sector accordingly. Although earnings were not poor, they were not enough to support the market, as investors now ask who will profit, what margins look like, and when the promise of AI will be fulfilled. A widely shared X post argues that AI requires heavy upfront spending, long payback periods and profits tied to keeping infrastructure running, so the economic moat has shifted from code to cash. The speakers see utilities as cash generators rather than growth stocks and suggest Big Tech may become a hybrid, but Barron's Al Root called the view a familiar argument that AI monetization may not justify the spending.
- Former Microsoft and Cisco Security Executive Edna Conway Joins Known Advisory Council
Known, a company building accountability infrastructure for autonomous AI, announced that Edna Conway has joined its Advisory Council. Conway previously served as Vice President and Chief Security & Risk Officer for Cloud Infrastructure at Microsoft and as Chief Security Officer for the Global Value Chain at Cisco, and currently works as Chief Operating and Risk Officer at TPO Group and CEO of EMC Advisors. Interim CEO Allie Kline said that as AI agents operate across organizational and platform boundaries, establishing who they represent and who is accountable is becoming critical, and that Known will advance DNSid as an open foundation for accountability.
- Earnings from Apple, Palantir, and jobs report data: What to Watch
The article previews key stories for investors in the week of Nov. 2. The focus is on earnings calls from Apple (AAPL) and Palantir (PLTR), along with the latest jobs report data being released.
- Western Gold Exploration Intersects 3.9 m @ 7.17 g/t Gold in Maiden Drilling at the Caledonian Gold Project, Scotland
Western Gold Exploration (TSXV: WGLD) reported results from its maiden drilling at the Coire a'Ghabhalach (CaG Vein) target in the Caledonian Gold Project, Scotland, with 4 diamond holes totalling 667 m. Across 7 holes in the Lyon area, about 1,260 m was drilled, while results from 3 holes at Creag Sheileach are pending. Hole GLDD26_004 intersected 3.9 m grading 7.17 g/t Au, 27.8 g/t Ag, 2.1% Zn and 6.51% Pb from 86.0 m, including 0.5 m at 42.8 g/t Au. Gold-bearing veins were intercepted in all four holes and remain open along strike and down dip. The company is evaluating follow-up work, including a ground IP geophysical survey and a soil grid extension to trace the vein along strike before further drilling.
- Astera Labs Fell Harder Than the Market in the AI Selloff. Here's What November 3 Must Show
Astera Labs (ALAB) fell 11% on October 30, nearly four times the Nasdaq Composite's 2.9% drop, amid broader AI spending worries sparked by news from Alphabet, Amazon and Intel rather than Astera itself. The company reports third-quarter results after the close on November 3. Analysts expect 2026 revenue of $1.91 billion, which the article says requires a fourth-quarter guide of $648 million to $668 million to stay intact. Gross margin is guided to about 72% for the third quarter, down from 76.3% in the first quarter, with roughly half the decline from a non-cash Amazon warrant charge and the rest from hardware mix. At 46x forward earnings, versus a one-year average of 72x, the stock sits near the bottom of its range.
- Premarket movers: Estee Lauder, Rivian rise premarket; Check Point falls
U.S. stock index futures pointed higher on Monday, with investors turning to Apple for shelter from AI spending concerns ahead of Tuesday's midterm elections. Estee Lauder rose 2.4% premarket after raising its annual sales and profit forecasts, with quarterly sales up 7% to $3.72 billion. Check Point Software fell 9.9% after a weaker-than-expected fourth-quarter revenue forecast, while Rivian gained 3.2% to $12.55 after UBS upgraded it to Buy from Neutral with a $17 price target. Okta rose 2.7% after S&P Dow Jones Indices selected it to join the S&P 500, replacing Kenvue before the open on Wednesday, November 4.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.